How generics get approved
The FDA pathway from application to pharmacy shelf. 26 articles: 2 data story, 23 explainers, 1 history.
The approval pathway
ANDA review goal dates and how often generics clear the first cycle
FDA meets its 10-month goal for acting on most generic applications, but only about one approval in five comes on the first review. How GDUFA goal dates work and what FDA's numbers show.
Complete response letters for generic drugs
FDA sends nearly two rejection letters for every generic it approves. What a complete response letter must contain, what FDA's own analyses say they cite, and why generic letters are not public.
New chemical entity exclusivity and the four-year door for generics
A drug with a never-approved active moiety gets five years in which no generic may even be filed, with an opening at year four for patent challengers. How NCE and three-year exclusivity work, and how to read the codes.
Orphan drug exclusivity and the generics it blocks
A rare-disease approval can bar copies of the same drug for the same use for seven years, patent or no patent. How the protection works, the court fight over its scope, and why generics often launch around it.
Pediatric exclusivity and the six months it adds before generics
A brand company that studies its drug in children at FDA's written request can win six more months of protection from generics. How the 1997 incentive works, what it attaches to, and what FDA's own lists show.
Reference listed drug, reference standard and basis of submission, explained
Every generic copies one approved product and is tested against another, and they are often not the same pill. How FDA defines the RLD and the reference standard, and what the Orange Book shows for common generics.
Bioequivalence and the 80-125 rule
The 80 to 125 percent range is a statistical test on blood levels. It does not let a generic hold 20 percent less drug. How the test works, what FDA's May 2026 guidance says, and what 2,070 studies showed.
How a generic drug gets approved
Every US generic goes through an Abbreviated New Drug Application. What goes into one, how FDA reviews it, the GDUFA III deadlines, and why a finished review can still end in a tentative approval.
Tentative approval, when FDA clears a generic that cannot yet be sold
What a tentative approval is, why finished generic applications wait in that status for patents and exclusivity to lapse, and how the same tool supplies HIV drugs to PEPFAR.
The Orange Book explained
FDA's Orange Book lists every approved drug, the patents and exclusivities that delay generics, and which copies FDA rates as substitutable. How each section works, and what changed in 2021.
The Hatch-Waxman Act explained
The 1984 law traded a fast generic pathway for extra patent life and new exclusivity for brands. How each side of the deal works, how the caps are calculated, and what Congress has changed since.
Equivalence & alternatives
FDA's Inactive Ingredient Database and the limits on excipients
A generic that uses more of an inactive ingredient than FDA's database lists can be refused at the door. What the Inactive Ingredient Database contains, how applicants use it, and where FDA says it stops.
Narrow therapeutic index drugs and the tighter test for their generics
Warfarin, levothyroxine, phenytoin and a few other drugs face a stricter generic test scaled to the brand's own variability. How it works, which drugs it covers and where state law adds rules.
Q1/Q2 sameness, the recipe rule for generic injectables, eye drops and creams
Generic injectables and eye and ear drops must match the brand's inactive ingredients to within 5 percent. How FDA applies the rule, where it bends, and what a February 2026 law now makes the agency disclose.
Authorized generics are the brand drug under a generic label
How an authorized generic differs from an ordinary generic, why brand companies launch them during the first filer's 180 days, what the FTC found about prices and settlements, and how to read FDA's list.
Complex generics and why some drugs still have few or no copies
Inhalers, peptide injections, creams and long-acting shots are hard to copy. What FDA counts as complex, how its product-specific guidances and pre-ANDA meetings work, and what recent approvals show.
How biosimilars differ from generics
Biosimilars and generics are approved under different laws and sameness tests. How the 351(k) pathway works, what interchangeability means at the pharmacy, and how many biosimilars FDA had approved by October 2026.
The 505(b)(2) pathway, between brand and generic
How FDA's hybrid new drug application works, how it differs from a full NDA and a generic ANDA, and what three years of approval data show about who uses it.
What therapeutic equivalence codes like AB, AA and BX mean
The two-letter codes in FDA's Orange Book tell pharmacists which generics FDA rates as interchangeable with a brand. All 16 codes, the numbered AB1 and AB2 variants, and how state laws use them.
FDA programs
Generic drug approvals in 2025, by the numbers
FDA counted 689 final generic approvals in fiscal 2025. GxRadar's calendar-year count from FDA's own database finds 648. What each total measures, what got approved, and the first generics FDA singled out.
Pre-ANDA meetings and FDA's advice program for complex generics
Before filing, developers of complex generics can ask FDA for formal meetings. Which products qualify, what each meeting offers, how often FDA grants them, and how GDUFA IV would rebuild the program.
What FDA's yearly first generics lists show
FDA's 2025 first generics list has 91 entries, but one entry is not one medicine and approval is not launch. What the lists count, and what price data show after a first copy arrives.
Competitive generic therapy, the FDA program for drugs with one maker
Since 2017 FDA can fast-track and reward generics of drugs with one or no generic competitor. The rules, the separate 180-day exclusivity, and what FDA's list of 531 CGT approvals shows.
FDA's product-specific guidances, the study plans behind each generic
FDA has published 2,447 product-specific guidances telling generic makers what studies it expects for a given drug. About 98 percent are still drafts. What they say, and why they matter most for complex products.
GDUFA, the user fees that pay for generic drug review
Generic makers will pay FDA about $666 million in fiscal 2027, including $375,684 per application. What the fees buy, how the program has changed since 2012, and where the 2027 renewal stands.
Inside FDA's Office of Generic Drugs
The FDA office that reviews every US generic approved 689 applications in fiscal 2025 and sent nearly twice as many rejection letters. How it is organized, what its numbers show, and how a review moves.